FMP
Silexion Therapeutics LTD
SLXN
NASDAQ
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
0.703 USD
-0.0187 (-2.66%)
SLXN Financial Statements
Year
2024
2023
2022
Current Assets
2.25M
4.98M
8.84M
Cash & Short Term Investments
1.19M
4.59M
8.26M
Cash And Cash Equivalents
0
4.59M
8.26M
Short Term Investments
0
0
0
Net Receivables
0
0
0
Inventory
0
0
0
Other Current Assets
97k
49k
67k
Non-Current Assets
613k
277k
494k
Property, Plant & Equipment
560k
247k
464k
Goodwill And Intangible Assets
0
0
0
Goodwill
0
0
0
Intangible Assets
0
0
0
Long Term Investments
0
0
0
Tax Assets
0
0
0
Other Non-Current Assets
53k
30k
30k
Other Assets
0
0
0
Total Assets
2.86M
5.26M
9.33M
-
-
-
Current Liabilities
3.52M
2.2M
1.61M
Accounts Payable
929k
319k
240k
Short Term Debt
158k
0
0
Tax Payables
0
0
0
Deferred Revenue
0
0
0
Other Current Liabilities
2.44M
407k
256k
Total Current Liabilities
3.52M
2.2M
1.61M
Total Non-Current Liabilities
3.33M
15.12M
14.8M
Long-Term Debt
368k
0
0
Deferred Revenue
0
0
0
Deferred Taxes Liabilities
0
0
0
Other Non Current liabilities
2.96M
15.06M
14.65M
Total Liabilities
6.85M
17.31M
16.41M
Other Liabilities
0
0
0
Stockholders Equity
-2k
-15.48M
-10.66M
Common Stock
2k
1k
1k
Retained Earnings
-43.25M
-26.81M
-21.87M
Accumulated Other Comprehensive Income/Loss
0
0
0
Other Shareholders Equity
43.25M
0
0
Total Liabilities and Stockholders Equity
2.86M
5.26M
9.33M
All figures are in USD.
